Dr. Robert Occhipinti, MD

Dr. Occhipinti practices at Touro Infirmary in New Orleans, Louisiana, part of LCMC Health.

Dr. Occhipinti's NPI, 1023112679, was assigned on September 12, 2006. Dr. Occhipinti holds Louisiana license 024928.

Dr. Occhipinti's primary practice is Touro Infirmary, at 1401 Foucher Street, New Orleans, LA 70115 in Orleans Parish. The practice phone is (504) 897-8247.

Dr. Occhipinti's primary practice is Touro Infirmary in New Orleans, Louisiana, part of LCMC Health. Dr. Occhipinti is also affiliated with Ochsner Medical Center - New Orleans. The medical group on file is Crescent City Physicians, Inc. Dmand AI also links Dr. Occhipinti to 3 more hospitals, 1 clinical lab and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Occhipinti practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Occhipinti's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Occhipinti is licensed in Louisiana.

CMS data shows 863 Medicare services from Dr. Occhipinti across 6 procedure codes in 2024, for 458 Medicare patients. Medicare paid $72,724 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 458 Medicare patients who saw Dr. Occhipinti in 2024. The largest group is 65 to 74, with 204 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Occhipinti's median patient age at 70, with 50% women.

In 2024, Dr. Occhipinti wrote 12,966 Medicare Part D claims for 1,000 patients. 85% of them were for generic drugs. CMS names the drug for 12,108 of them, across 170 drugs with 11 or more claims each, at $1,202,286 in total drug cost. In 2023, CMS named 10,702 claims across 154 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Occhipinti for performance year 2024, reported as part of a group. Dr. Occhipinti accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 555 general payments to Dr. Occhipinti from 42 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,020.